Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?
- PMID: 28581473
- DOI: 10.1038/bmt.2017.104
Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?
Comment on
-
Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.Bone Marrow Transplant. 2017 Jul;52(7):962-968. doi: 10.1038/bmt.2017.16. Epub 2017 Feb 27. Bone Marrow Transplant. 2017. PMID: 28244980 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
